At BIO USA Press Conference

Bio Research Center at the Core


Strengthening CDMO Technological Competitiveness

Announces Proprietary Platform Licensing-Out Strategy

Samsung Biologics is aiming to secure a dominant edge in contract development and manufacturing organization (CDMO) technology, with its Bio Research Center at the core. By licensing out its proprietary platforms, the company plans to generate new revenue streams, while also internalizing cutting-edge technologies ahead of the competition to gain future competitive advantages.


Jung Hyungnam, Vice President and Head of the Bio Research Center at Samsung Biologics, presented the results of next-generation advanced technology research and business strategy at a media briefing during BIO USA in San Diego, USA, on the 24th (local time). Established in July 2022, the Bio Research Center focuses on research in production platforms, antibody platforms, and new modalities (therapeutic approaches), leveraging more than 100 master's and PhD-level experts across the life sciences.


Jung Hyungnam, Vice President and Head of the Bio Research Center at Samsung Biologics, is explaining about the Bio Research Center during a Samsung Biologics division meeting held on the 24th (local time) in San Diego, USA, during BIO USA. Samsung Biologics

Jung Hyungnam, Vice President and Head of the Bio Research Center at Samsung Biologics, is explaining about the Bio Research Center during a Samsung Biologics division meeting held on the 24th (local time) in San Diego, USA, during BIO USA. Samsung Biologics

View original image

Jung stated, "The core strategy of the center is to support our key CDMO business through the development of world-class production platforms and process technologies," adding, "We will proactively sense and internalize next-generation emerging technologies to secure future technologies with clear differentiation and competitive advantages."


In the area of production platforms, the company maximizes productivity with its proprietary cell line platforms, S-CHOice and S-AfuCHO. It is also actively adopting continuous process technology, which enables cost reduction and automation. Unlike conventional large-scale batch processes that require extensive space, continuous production can be carried out on a smaller scale, increasing material utilization. Jung noted, "Case studies have shown that productivity is about twice as high compared to existing production methods," and explained, "We have established a hybrid continuous process that can be used alongside conventional methods, and have also internalized automation and process analytical technology (PAT)." Looking ahead, Samsung Biologics plans to secure fully continuous process technology, implement pilot manufacturing, and gradually expand its GMP-compliant manufacturing facilities.


For antibody platforms, the company is conducting primate safety testing on its bispecific antibody platform, S-DUAL. Jung emphasized, "Through collaboration with AimedBio, we are developing a differentiated linker-payload to overcome the limitations of single-antibody-based next-generation antibody-drug conjugates (ADCs)," adding, "We will continue to demonstrate the scalability of our platform, based on high bystander cell-killing effects and low toxicity." To address the low brain penetration of antibody therapeutics, the company is also developing a shuttle platform targeting novel markers expressed only at the blood-brain barrier (BBB), differentiating it from existing treatments.


The company is also accelerating the discovery of next-generation modalities. Samsung Biologics has established an adeno-associated virus (AAV) process platform and a high-productivity proprietary vector platform, while enhancing the production process for a wide range of serotypes. In the messenger RNA (mRNA) sector, it has secured untranslated regions and polyA sequences that improve expression levels and stability over existing drugs. In addition, for chimeric antigen receptor (CAR)-T therapies, the company has internalized target-specific lipid nanoparticle (LNP) technology, which addresses the limitation of previous LNPs being delivered only to the liver.


The company has also strengthened its investment base for the early acquisition of promising technologies. The newly established Technology Business Development (Technology BD) Group is investing in companies specializing in ADC, AAV, and artificial intelligence (AI), including through the third Samsung Life Science Fund (LS Fund 3), which was created this year with a size of KRW 200 billion. Jung stated, "By licensing out our proprietary platforms, we will support the development of next-generation drugs linked to CDMO," adding, "We are proactively internalizing market-leading new technologies by selectively adopting them."



Meanwhile, Samsung Biologics clarified that its advanced technologies under development are not intended for its own new drug development. Jung said, "The technologies we are developing are part of a business model to meet and collaborate with client needs as a CDMO company," adding, "We hope it will not be misunderstood that the company is directly pursuing new drug development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing